Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medigen Vaccine Biologics Corp. (6547.TWO)
Zhubei, TPE, TW
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation operates as a subsidiary of Medigen Biotechnology Corp.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.73% | -0.21% | -13.85% | +32.69% | +29.28% | +26.89% | -4.39% | -18.12% | -80.36% | +158.18% | +169.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1.2% Q1'26: -8.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-258.3% Q1'26: -50.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-21.1% Q1'26: +92.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-43.3% Q1'26: -30.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-13.4% ★ Q1'26: -6.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.3% ★ Q1'26: -10.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.29× Q1'26: -2.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
11.51M
est: 11.50M (+0.1%)
|
3.28B
est: 7.08B (-53.7%)
|
365.04M
est: 2.84B (-87.2%)
|
389.62M
est: 13.00M (+2,897.1%)
|
605.64M
est: 654.00M (-7.4%)
|
613.17M
est: 695.00M (-11.8%)
|
865.00M
865.00M – 865.00M
+24.5% YoY
|
1.59B
1.59B – 1.59B
+83.7% YoY
|
| EBITDA |
-535.61M
est: -5.54M (-9,561.1%)
|
1.53B
est: -3.41B (+144.8%)
|
-1.32B
est: -1.37B (+3.7%)
|
-991.09M
est: -6.27M (-15,714.2%)
|
74.87M
est: -210.91M (+135.5%)
|
-123.90M
est: -224.14M (+44.7%)
|
-278.96M
-278.96M – -278.96M
-24.5% YoY
|
-512.45M
-512.45M – -512.45M
-83.7% YoY
|
| EBIT |
-657.86M
est: -6.14M (-10,612.6%)
|
963.73M
est: -3.78B (+125.5%)
|
-1.45B
est: -1.52B (+4.6%)
|
-1.12B
est: -6.94M (-16,066.2%)
|
-61.58M
est: -275.11M (+77.6%)
|
-265.69M
est: -292.36M (+9.1%)
|
-363.87M
-363.87M – -363.87M
-24.5% YoY
|
-668.43M
-668.43M – -668.43M
-83.7% YoY
|
| Net Income |
-690.70M
est: -759.70M (+9.1%)
|
1.41B
est: 1.59B (-11.3%)
|
-1.50B
est: 192.84M (-878.6%)
|
-1.16B
est: -719.77M (-61.1%)
|
-80.47M
est: -62.24M (-29.3%)
|
-281.71M
est: 75.34M (-473.9%)
|
124.48M
124.48M – 124.48M
+65.2% YoY
|
478.26M
478.26M – 478.26M
+284.2% YoY
|
| SGA |
91.96M
est: 22.30M (+312.4%)
|
148.21M
est: 13.73B (-98.9%)
|
183.67M
est: 5.51B (-96.7%)
|
243.44M
est: 25.20M (+865.8%)
|
320.58M
est: 275.54M (+16.3%)
|
247.78M
est: 292.81M (-15.4%)
|
364.43M
364.43M – 364.43M
+24.5% YoY
|
669.46M
669.46M – 669.46M
+83.7% YoY
|
| EPS |
-2.48
est: -2.31 (-7.3%)
|
4.47
est: 4.84 (-7.6%)
|
-4.64
est: 0.59 (-890.8%)
|
-3.53
est: -2.19 (-61.2%)
|
-0.24
est: -0.19 (-26.3%)
|
-0.86
est: 0.23 (-473.9%)
|
0.38
0.38 – 0.38
+65.2% YoY
|
1.46
1.46 – 1.46
+284.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.29M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 92.8K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 41.1K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 4.58M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 63.0K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 5.17M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 300.5K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 7.4K | 0.22% |
| 9 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 3.8K | 0.24% |
| 10 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 3.8K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jia-En Liang | Deputy General Manager of International & Public Affairs | 8M | male |
| Yu-Ping Yang | Chief Financial Officer & Vice President of Administration Division | 5M | female |
| Cheng-Yang Chen | Head of Project Management Department | 3M | male |
| He-Ru Hsieh | Head of Production Dept | 3M | male |
| Leo Lee | Chief Executive Officer & Executive Vice President | — | — |
| Qing-An Wu | Head of Regulatory Affairs Dept. | — | male |
| Huai-En Gan | Deputy Head of Department | — | — |
| Szu-hsien Lee | President | — | male |
| Yu Ping Yang | Accounting Supervisor | — | — |
| Shih-Shen Lee | Executive Vice President of Operations Business Unit | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6547.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
